Doxycycline Improves Pathology in Lymphatic Filariasis
Author Information
Author(s): Debrah Alexander Yaw, Mand Sabine, Specht Sabine, Marfo-Debrekyei Yeboah, Batsa Linda, Pfarr Kenneth, Larbi John, Lawson Bernard, Taylor Mark, Adjei Ohene, Hoerauf Achim
Primary Institution: Institute for Medical Microbiology, Immunology, and Parasitology, University of Bonn, Bonn, Germany
Hypothesis
Can doxycycline reduce plasma VEGF-C/sVEGFR-3 levels and improve pathology in patients with lymphatic filariasis?
Conclusion
Doxycycline treatment significantly reduced plasma levels of VEGF-C/sVEGFR-3 and improved clinical conditions in lymphatic filariasis patients.
Supporting Evidence
- Doxycycline reduced Wolbachia levels by 95% in treated patients.
- Significant reductions in microfilaremia were observed at 12 and 24 months post-treatment.
- Plasma levels of VEGF-C and sVEGFR-3 decreased significantly in doxycycline-treated patients.
- Clinical improvement in lymphedema stages was noted in doxycycline-treated patients.
- Adverse reactions were mild and did not require treatment cessation.
Takeaway
Doxycycline can help people with lymphatic filariasis by making them feel better and reducing harmful substances in their blood.
Methodology
A double-blind, placebo-controlled trial was conducted with 95 patients receiving either doxycycline or placebo for 6 weeks, followed by monitoring of various health indicators.
Potential Biases
Potential biases may arise from the placebo-controlled design and patient selection.
Limitations
The study was limited to a specific geographic area and may not be generalizable to all populations.
Participant Demographics
76 microfilaremic patients and 19 lymphedema patients, with a mix of genders.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website